32932 Pacific Coast Highway
Suite 14-254
Dana Point, CA 92629
United States
321 299 2014
https://www.agentixcorp.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees:
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Salman Hoda | CEO, Senior VP Portfolio & Business Development, Secretary, Treasurer and Director | N/A | N/A | 1981 |
Martin Schroeder | Chief Scientific Officer & Member of Scientific Advisory Board | N/A | N/A | N/A |
Mr. David Fiene | Controller | N/A | N/A | N/A |
Agentix Corp., a clinical development stage company, focuses on the development and commercialization of novel therapeutics to treat metabolic diseases. Its product pipeline includes AGTX-2004, a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, which has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver diseases. The company was formerly known as FairWind Energy, Inc. and changed its name to Agentix Corp. in June 2019. Agentix Corp. was founded in 2020 and is based in Dana Point, California.
Agentix Corp.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.